MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of ...

LA JOLLA, Calif. (AP) — LA JOLLA, Calif. (AP) — MediciNova Inc. (MNOV) on Wednesday reported a loss of $2.9 million in its third quarter. On a per-share basis, the La Jolla, California-based company ...

MediciNova (MNOV) was notified by Sanofi (SNY) that the Sanofi/Novartis (NVS) litigation was settled. Accordingly, MediciNova is entitled to ...

MediciNova, Inc. (NASDAQ:MNOV – Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday .The stock has a 200-day moving average of $1.50 and traded as high ...

StockNews.com assumed coverage on shares of MediciNova (NASDAQ:MNOV – Free Report) in a report released on Wednesday. The firm issued a hold rating on the biopharmaceutical company’s stock. MediciNova ...

LA JOLLA, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock ...

MediciNova (MNOV) announced the lead Principal Investigator of this clinical trial, Bjorn Oskarsson, MD, FAAN presented the update of an ongoing Phase 2/3 clinical trial of MN-166 in Amyotrophic ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug ...

Net income of $1.5 millionAdjusted EBITDA1 of $1.9 millionADHD Portfolio net revenue up 1% to $15.3 millionPediatric Portfolio net revenue up 54% sequentially$20.1 million cash balance at September 30 ...

Shares of MariaDB plc (NYSE: MRDB) rose sharply in today’s pre-market trading after Progress Software (NASDAQ: PRGS) announced that it is possibly considering an offer for the company. Avi ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug ...